BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) --  Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding term sheet with a privately held, commercial-stage health diagnostics and toxicology testing company (the 'Dx Company').

加利福尼亚州伯克利，2026年7月27日（环球电讯社）——数字健康公司Profusa, Inc.（纳斯达克股票代码：PFSA），作为下一代生物传感技术的先驱，宣布与一家处于商业化阶段的私营健康诊断和毒理学检测公司（简称“Dx公司”）签署了一份无约束力的条款清单。

Following the contemplated transaction, the combined company is expected to operate as a public diagnostics company with national CLIA-certified laboratories, recurring revenues from a diversified base of providers serving addiction treatment, pain management, and behavioral health. The Dx Company’s 2025 Net Revenues are estimated, based on unaudited management information, to be approximately $111 million..

在完成拟议交易后，合并后的公司预计将作为一家公共诊断公司运营，拥有获得全国CLIA认证的实验室，并从服务于成瘾治疗、疼痛管理和行为健康的多元化提供商基础中获得经常性收入。根据未经审计的管理层信息，Dx公司2025年的净收入估计约为1.11亿美元。

Mr. Jack Stover, a director of Profusa, has been appointed by the Profusa Board of Directors as Executive Chairman of the Board of Directors and Chief Executive Officer. Ben Hwang, PhD, formerly the Chief Executive Officer, Chairman, and Director of the Board of Profusa, has transitioned into the role of President of Profusa.

Profusa 董事 Jack Stover 先生已被 Profusa 董事会任命为董事会执行主席兼首席执行官。此前担任 Profusa 首席执行官、董事会主席及董事的 Ben Hwang 博士，已转任 Profusa 总裁。

Liviu Goldenberg has been appointed by the Profusa Board of Directors as an independent director. Mr. Goldenberg has 30+ years of global leadership experience overseeing complex operations, technology adoption, and enterprise transformation. He has deep expertise in technology-enabled manufacturing, AI / IIoT platforms, sustainability, capital deployment, and risk oversight.

Liviu Goldenberg已被Profusa董事会任命为独立董事。Goldenberg先生拥有30多年的全球领导经验，负责监督复杂运营、技术采用和企业转型。他在技术驱动的制造、人工智能/工业物联网平台、可持续发展、资本配置和风险监管方面具有深厚的专业知识。

Mr. Goldenberg is also an active advisor to growth-stage and scale-up technology companies, with experience supporting capital raises, strategic partnerships, and institutional initiatives and importantly brings disciplined governance judgment, independence, and a long-term shareholder focus..

戈登伯格先生还积极担任成长期和扩张期科技公司的顾问，在支持融资、战略合作伙伴关系以及机构倡议方面拥有丰富经验，更重要的是，他带来了严谨的治理判断力、独立性以及对长期股东价值的关注。

It is anticipated that upon the execution of a definitive acquisition agreement (the 'Acquisition Agreement'), Profusa will issue to the Dx Company stockholders the following consideration: (i) shares of Profusa common stock equal to 19.99% of Profusa's then issued and outstanding common shares; and (ii) the remainder of the consideration in the form of shares of Profusa non-voting convertible preferred stock (the 'Preferred Stock'), which will be convertible into Profusa common shares subject to a stockholder approval by Profusa's stockholders (together, the 'Consideration').

预计在执行最终收购协议（“收购协议”）时，Profusa 将向 Dx Company 股东支付以下对价：(i) 相当于 Profusa 当时已发行及流通在外普通股总数 19.99% 的 Profusa 普通股股份；以及 (ii) 剩余对价以 Profusa 无投票权可转换优先股（“优先股”）的形式支付，该等优先股可在获得 Profusa 股东批准的前提下转换为 Profusa 普通股股份（合称“对价”）。

In addition, it is expected that Profusa's outstanding convertible notes and obligations will also be exchanged for Preferred Stock..

此外，预计Profusa的未偿还可转换票据和债务也将交换为优先股。

Concurrently with the closing of the transaction and subject to due diligence and documentation, Profusa expects to close on approximately $7 million of necessary financing (subordinated to existing bank debt) in the form a convertible note (the 'Notes'), all or portions of which may be provided by existing investors in Profusa.

在交易交割的同时，并以待完成的尽职调查和文件签署为前提，Profusa 预计将以可转换票据（“票据”）的形式完成约 700 万美元的必要融资（该融资次于现有银行债务），全部或部分资金可能由 Profusa 的现有投资者提供。

Indicative terms of the Notes include a 12-month term, a 9% original issue discount (OID), and a 7% interest rate per year (18% in the event of a default)..

票据的指示性条款包括12个月的期限、9%的原始发行折扣（OID）以及每年7%的利率（若发生违约，则为18%）。

About Profusa

关于Profusa

Profusa is a digital health company developing a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable, and affordable biosensors and intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.

Profusa 是一家数字健康公司，致力于开发新一代组织集成传感器，以检测并持续传输可供个人和医疗使用的、可操作的医疗级数据。凭借其长效、可注射且经济实惠的生物传感器以及智能数据平台，Profusa 旨在为人们提供个性化的生化特征谱，该特征谱基于临床医生可以信任和依赖的数据。

For more information, please visit .

更多信息，请访问。

www.profusa.com

www.profusa.com

.

。

'LUMEE', 'PROFUSA' and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea, and Australia.

“LUMEE”、“PROFUSA”以及PROFUSA标志是Profusa, Inc.在美国、加拿大、欧盟、中国、日本、韩国和澳大利亚的注册商标。

About the Dx Company

关于Dx公司

The Dx Company provides laboratory testing solutions, clinical insight, and reporting tools that help healthcare teams make informed treatment decisions, streamline workflows, and improve patient outcomes. Its CLIA-certified and CAP/CLIA accredited national medical laboratories provide molecular diagnostic tests for infectious disease and urine and blood clinical toxicology testing, with a client base serving addiction treatment, pain management, and behavioral health providers across the country..

Dx公司提供实验室检测解决方案、临床洞察和报告工具，帮助医疗团队做出明智的治疗决策、优化工作流程并改善患者预后。其拥有CLIA认证及CAP/CLIA认可的全国性医学实验室提供感染性疾病分子诊断测试以及尿液和血液临床毒理学检测，客户群体涵盖全国范围内的成瘾治疗、疼痛管理和行为健康服务机构。

Special Note Regarding Forward-Looking Statements

关于前瞻性陈述的特别说明

Certain statements in this press release may be considered 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa, including statements regarding the proposed acquisition, the anticipated launch of PanOmics DX™, Profusa's strategic plans, the proposed business combination with the Dx Company, the expected operating results of the Dx Company, the terms and amounts of the financings expected to be consummated in connection with the Dx business combination.

本新闻稿中的某些陈述可能被视为1995年美国《私人证券诉讼改革法》“安全港”条款所定义的“前瞻性陈述”。前瞻性陈述通常涉及未来事件或Profusa未来的财务或经营业绩，包括关于拟议收购、PanOmics DX™的预期推出、Profusa的战略计划、与Dx公司拟议的业务合并、Dx公司的预期经营业绩，以及与Dx业务合并相关预计完成的融资条款和金额的陈述。

In some cases, you can identify forward-looking statements by terminology such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'future,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'propose,' 'seek,' 'should,' 'strive,' 'will,' or 'would' or the negatives of these terms or variations of them or similar terminology..

在某些情况下，您可以通过诸如“预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“预测”、“未来”、“打算”、“可以”、“或许”、“计划”、“有可能”、“潜在”、“预见”、“规划”、“提议”、“寻求”、“应当”、“努力”、“将”或“会”等术语，以及这些术语的否定形式、变体或类似表述，来识别前瞻性陈述。

Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, without limitation, risks related to Profusa’s planned European and U.S.

此类前瞻性陈述受限于风险、不确定性及其他可能超出Profusa控制范围的因素，这些因素可能导致实际结果与此类前瞻性陈述所明示或暗示的结果存在重大差异，包括但不限于与Profusa计划的欧洲和美国业务相关的风险。

product launches, the risk that such product launches may not result in revenue at the levels anticipated, the risk that customer demand may be less than expected, the risks in negotiating, concluding and closing definitive acquisition agreements, as well as the risks in complying with the representations, warranties and covenants set forth in those agreements if they are executed, and risks related to the completion and terms of the contemplated financings..

产品发布、此类产品发布可能无法达到预期收入水平的风险、客户需求可能低于预期的风险、在谈判、达成和签署最终收购协议过程中的风险，以及若执行这些协议，则需遵守其中所载陈述、保证和承诺的相关风险，以及与拟议融资的完成及条款相关的风险。

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. There are risks and uncertainties described more fully in Profusa's public filings from time to time with the U.S. Securities and Exchange Commission (the 'SEC'), including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.

这些前瞻性陈述基于某些估计和假设，尽管Profusa及其管理层认为这些估计和假设是合理的，但它们本质上具有不确定性。有关风险和不确定性的更详细描述，请参阅Profusa不时向美国证券交易委员会（“SEC”）提交的公开文件，包括其最新的10-K表格年度报告、10-Q表格季度报告和8-K表格当前报告。

These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate..

这些备案文件可能识别并阐述其他重要的风险和不确定性，这些因素可能导致实际事件和结果与前瞻性陈述中包含的内容存在重大差异。Profusa 无法保证本沟通文件中的前瞻性陈述将被证实为准确无误。

Investor and Media Contact

投资者与媒体联系人

info@coreir.com

info@coreir.com

212-655-0924

212-655-0924

#   #   #

# # #